Skip to main content

Table 5 Outcome in ITT and clinically evaluable patients

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Parameter

Infusion

Bolus

P- value

Number of patients

   

ITT

120

120

 

Clinically evaluable

106

108

 

Meropenem-related length of mechanical ventilation

   

ITT

9 (5 to 13)

11 (6 to 17)

0.051

Clinically evaluable

9 (5 to 15)

12 (6 to 19)

0.058

Meropenem-related ICU LOS

   

ITT

10 (7 to 14)

12 (7 to 19)

0.044

Clinically evaluable

10 (7 to 16.5)

13 (8 to 21)

0.042

Meropenem-related hospital LOS

   

ITT

26 (17 to 38)

22 (12 to 35)

0.079

Clinically evaluable

28 (18 to 39)

25 (14 to 42)

0.412

ICU mortality

   

ITT

18 (15.0%)

25 (20.8%)

0.313

Clinically evaluable

14 (11.6%)

17 (14.2%)

0.701

Hospital mortality

   

ITT

21 (17.5%)

28 (23.3%)

0.337

Clinically evaluable

17 (16.0%)

19 (15.7%)

0.857

Duration of meropenem therapy (days)

   

ITT

7 (5 to 8)

8 (6 to 9)

0.041

Clinically evaluable

7 (6 to 8)

8 (7 to 10)

0.035

Total dose of meropenem (g)

   

ITT

24 (21 to 32)

48 (42 to 48)

< 0.0001

Clinically evaluable

24 (24 to 32)

48 (42 to 60)

< 0.0001

  1. Values are presented as absolute (percentage) or median (interquartile range). ICU, intensive care unit; ITT, intention-to-treat; LOS, length of stay